» Articles » PMID: 20360906

Medical Treatment of Cushing's Disease: Overview and Recent Findings

Overview
Journal Int J Gen Med
Publisher Dove Medical Press
Specialty General Medicine
Date 2010 Apr 3
PMID 20360906
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Cushing's disease, due to pituitary adrenocorticotropic hormone (ACTH) hypersecretion, is the most common etiology of spontaneous excess cortisol production. The majority of pituitary tumors causing Cushing's disease measure <1 cm and the excess morbidity associated with these tumors is mostly due to the effects of elevated, nonsuppressible, ACTH levels leading to adrenal steroid hypersecretion. Elevated circulating cortisol levels lead to abnormal fat deposition, hypertension, diabetes, coronary artery disease, osteoporosis, muscle weakness and psychological disturbances. At experienced centers, initial surgical remission rate via transnasal, transphenoidal resection approaches 80% for tumors less than 1 cm, but may be as low as 30% for larger lesions and long-term recurrence in all groups approaches 25%. Residual disease may be managed with more radical surgery, pituitary-directed radiation, bilateral adrenalectomy, or medical therapy. This paper addresses current and novel therapies in various stages of development for Cushing's disease.

Citing Articles

A human ACTH-secreting corticotroph tumoroid model: Novel Human ACTH-Secreting Tumor Cell in vitro Model.

Zhang D, Hugo W, Redublo P, Miao H, Bergsneider M, Wang M EBioMedicine. 2021; 66:103294.

PMID: 33773184 PMC: 8024915. DOI: 10.1016/j.ebiom.2021.103294.


TSP-1 is downregulated and inversely correlates with miR-449c expression in Cushing's disease.

Ren J, Gu C, Yang Y, Xue J, Sun Y, Jian F J Cell Mol Med. 2019; 23(6):4097-4110.

PMID: 31016850 PMC: 6533510. DOI: 10.1111/jcmm.14297.


The risks of overlooking the diagnosis of secreting pituitary adenomas.

Brue T, Castinetti F Orphanet J Rare Dis. 2016; 11(1):135.

PMID: 27716353 PMC: 5052978. DOI: 10.1186/s13023-016-0516-x.


Targeting the ERK pathway for the treatment of Cushing's disease.

Zhang D, Bergsneider M, Wang M, Heaney A Oncotarget. 2016; 7(43):69149-69158.

PMID: 27708250 PMC: 5342466. DOI: 10.18632/oncotarget.12381.


Managing Cushing's disease: the state of the art.

Colao A, Boscaro M, Ferone D, Casanueva F Endocrine. 2014; 47(1):9-20.

PMID: 24415169 DOI: 10.1007/s12020-013-0129-2.


References
1.
Miller G, Alexander J, Bikkal H, Katznelson L, Zervas N, Klibanski A . Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 1995; 80(4):1386-92. DOI: 10.1210/jcem.80.4.7714115. View

2.
Shimon I . Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine. 2003; 20(3):265-9. DOI: 10.1385/ENDO:20:3:265. View

3.
Kurie J . The biologic basis for the use of retinoids in cancer prevention and treatment. Curr Opin Oncol. 1999; 11(6):497-502. DOI: 10.1097/00001622-199911000-00011. View

4.
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E . Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007; 356(1):29-38. DOI: 10.1056/NEJMoa062222. View

5.
Pivonello R, Faggiano A, Lombardi G, Colao A . The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am. 2005; 34(2):327-39, viii. DOI: 10.1016/j.ecl.2005.01.010. View